IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1IOVA - US4622601007 - Common Stock
2.323 EUR
+0.02 (+1%)
1IOVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. 1IOVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 1IOVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year 1IOVA has reported negative net income.
- 1IOVA had a negative operating cash flow in the past year.
- In the past 5 years 1IOVA always reported negative net income.
- 1IOVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -43.94%, 1IOVA is in line with its industry, outperforming 40.96% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -56.62%, 1IOVA is in line with its industry, outperforming 59.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| ROIC | N/A |
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- 1IOVA has a Gross Margin of 23.96%. This is comparable to the rest of the industry: 1IOVA outperforms 42.17% of its industry peers.
- 1IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- 1IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, 1IOVA has more shares outstanding
- 1IOVA has more shares outstanding than it did 5 years ago.
- 1IOVA has a better debt/assets ratio than last year.
2.2 Solvency
- 1IOVA has an Altman-Z score of -1.80. This is a bad value and indicates that 1IOVA is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of 1IOVA (-1.80) is worse than 63.86% of its industry peers.
- 1IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- 1IOVA has a better Debt to Equity ratio (0.00) than 92.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.8 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
- A Current Ratio of 3.41 indicates that 1IOVA has no problem at all paying its short term obligations.
- 1IOVA's Current ratio of 3.41 is fine compared to the rest of the industry. 1IOVA outperforms 67.47% of its industry peers.
- A Quick Ratio of 3.00 indicates that 1IOVA has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.00, 1IOVA is in the better half of the industry, outperforming 68.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
- 1IOVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.13%, which is quite impressive.
- 1IOVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 175.62%.
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%
3.2 Future
- Based on estimates for the next years, 1IOVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.02% on average per year.
- 1IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.94% yearly.
EPS Next Y17%
EPS Next 2Y24.23%
EPS Next 3Y22.59%
EPS Next 5Y19.02%
Revenue Next Year58.86%
Revenue Next 2Y59.19%
Revenue Next 3Y56.7%
Revenue Next 5Y41.94%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- 1IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1IOVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as 1IOVA's earnings are expected to grow with 22.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.23%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
- No dividends for 1IOVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI FAQ
Can you provide the ChartMill fundamental rating for IOVANCE BIOTHERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to 1IOVA.MI.
What is the valuation status of IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) stock?
ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI). This can be considered as Overvalued.
Can you provide the profitability details for IOVANCE BIOTHERAPEUTICS INC?
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) has a profitability rating of 1 / 10.